vs
Alector, Inc.（ALEC）与安进（AMGN）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是Alector, Inc.的1581.9倍（$9.9B vs $6.2M）。安进净利率更高（13.5% vs -597.5%，领先611.0%）。安进同比增速更快（8.6% vs -88.5%）。过去两年安进的营收复合增速更高（15.1% vs -37.4%）
Alector是一家临床阶段生物制药企业，专注于神经退行性疾病的免疫疗法研发，管线覆盖阿尔茨海默病、额颞叶痴呆、帕金森病等未被满足的医疗需求，主要在美国运营，与全球药企合作推进候选药物的临床试验。
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
ALEC vs AMGN — 直观对比
营收规模更大
AMGN
是对方的1581.9倍
$6.2M
营收增速更快
AMGN
高出97.1%
-88.5%
净利率更高
AMGN
高出611.0%
-597.5%
两年增速更快
AMGN
近两年复合增速
-37.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $6.2M | $9.9B |
| 净利润 | $-37.3M | $1.3B |
| 毛利率 | — | 69.8% |
| 营业利润率 | -634.4% | 27.6% |
| 净利率 | -597.5% | 13.5% |
| 营收同比 | -88.5% | 8.6% |
| 净利润同比 | -1696.9% | 112.6% |
| 每股收益（稀释后） | $-0.34 | $2.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALECAMGN
| Q4 25 | $6.2M | $9.9B | ||
| Q3 25 | $3.3M | $9.6B | ||
| Q2 25 | $7.9M | $9.2B | ||
| Q1 25 | $3.7M | $8.1B | ||
| Q4 24 | $54.2M | $9.1B | ||
| Q3 24 | $15.3M | $8.5B | ||
| Q2 24 | $15.1M | $8.4B | ||
| Q1 24 | $15.9M | $7.4B |
净利润ALECAMGN
| Q4 25 | $-37.3M | $1.3B | ||
| Q3 25 | $-34.7M | $3.2B | ||
| Q2 25 | $-30.5M | $1.4B | ||
| Q1 25 | $-40.5M | $1.7B | ||
| Q4 24 | $-2.1M | $627.0M | ||
| Q3 24 | $-42.2M | $2.8B | ||
| Q2 24 | $-38.7M | $746.0M | ||
| Q1 24 | $-36.1M | $-113.0M |
毛利率ALECAMGN
| Q4 25 | — | 69.8% | ||
| Q3 25 | — | 67.8% | ||
| Q2 25 | — | 67.2% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 65.7% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 61.4% | ||
| Q1 24 | — | 57.0% |
营业利润率ALECAMGN
| Q4 25 | -634.4% | 27.6% | ||
| Q3 25 | -1153.6% | 26.4% | ||
| Q2 25 | -433.6% | 28.9% | ||
| Q1 25 | -1216.5% | 14.5% | ||
| Q4 24 | -13.4% | 25.4% | ||
| Q3 24 | -315.7% | 24.1% | ||
| Q2 24 | -302.4% | 22.8% | ||
| Q1 24 | -275.0% | 13.3% |
净利率ALECAMGN
| Q4 25 | -597.5% | 13.5% | ||
| Q3 25 | -1063.4% | 33.7% | ||
| Q2 25 | -387.7% | 15.6% | ||
| Q1 25 | -1101.6% | 21.2% | ||
| Q4 24 | -3.8% | 6.9% | ||
| Q3 24 | -275.2% | 33.3% | ||
| Q2 24 | -256.4% | 8.9% | ||
| Q1 24 | -227.0% | -1.5% |
每股收益（稀释后）ALECAMGN
| Q4 25 | $-0.34 | $2.45 | ||
| Q3 25 | $-0.34 | $5.93 | ||
| Q2 25 | $-0.30 | $2.65 | ||
| Q1 25 | $-0.41 | $3.20 | ||
| Q4 24 | $-0.02 | $1.17 | ||
| Q3 24 | $-0.43 | $5.22 | ||
| Q2 24 | $-0.40 | $1.38 | ||
| Q1 24 | $-0.38 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $256.0M | $9.1B |
| 总债务越低越好 | $10.0M | $54.6B |
| 股东权益账面价值 | $30.6M | $8.7B |
| 总资产 | $293.2M | $90.6B |
| 负债/权益比越低杠杆越低 | 0.33× | 6.31× |
8季度趋势，按日历期对齐
现金及短期投资ALECAMGN
| Q4 25 | $256.0M | $9.1B | ||
| Q3 25 | $291.1M | $9.4B | ||
| Q2 25 | $307.3M | $8.0B | ||
| Q1 25 | $354.6M | $8.8B | ||
| Q4 24 | $413.4M | $12.0B | ||
| Q3 24 | $457.2M | $9.0B | ||
| Q2 24 | $503.3M | $9.3B | ||
| Q1 24 | $562.1M | $9.7B |
总债务ALECAMGN
| Q4 25 | $10.0M | $54.6B | ||
| Q3 25 | — | $54.6B | ||
| Q2 25 | — | $56.2B | ||
| Q1 25 | — | $57.4B | ||
| Q4 24 | $10.0M | $60.1B | ||
| Q3 24 | — | $60.4B | ||
| Q2 24 | — | $62.6B | ||
| Q1 24 | — | $64.0B |
股东权益ALECAMGN
| Q4 25 | $30.6M | $8.7B | ||
| Q3 25 | $57.7M | $9.6B | ||
| Q2 25 | $71.2M | $7.4B | ||
| Q1 25 | $94.6M | $6.2B | ||
| Q4 24 | $126.8M | $5.9B | ||
| Q3 24 | $118.9M | $7.5B | ||
| Q2 24 | $150.6M | $5.9B | ||
| Q1 24 | $178.9M | $5.0B |
总资产ALECAMGN
| Q4 25 | $293.2M | $90.6B | ||
| Q3 25 | $335.3M | $90.1B | ||
| Q2 25 | $356.4M | $87.9B | ||
| Q1 25 | $408.3M | $89.4B | ||
| Q4 24 | $468.3M | $91.8B | ||
| Q3 24 | $516.0M | $90.9B | ||
| Q2 24 | $570.7M | $90.9B | ||
| Q1 24 | $635.5M | $93.0B |
负债/权益比ALECAMGN
| Q4 25 | 0.33× | 6.31× | ||
| Q3 25 | — | 5.67× | ||
| Q2 25 | — | 7.57× | ||
| Q1 25 | — | 9.24× | ||
| Q4 24 | 0.08× | 10.23× | ||
| Q3 24 | — | 8.02× | ||
| Q2 24 | — | 10.57× | ||
| Q1 24 | — | 12.75× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-41.7M | $1.6B |
| 自由现金流经营现金流 - 资本支出 | — | $961.0M |
| 自由现金流率自由现金流/营收 | — | 9.7% |
| 资本支出强度资本支出/营收 | 0.0% | 6.5% |
| 现金转化率经营现金流/净利润 | — | 1.20× |
| 过去12个月自由现金流最近4个季度 | — | $8.1B |
8季度趋势，按日历期对齐
经营现金流ALECAMGN
| Q4 25 | $-41.7M | $1.6B | ||
| Q3 25 | $-32.5M | $4.7B | ||
| Q2 25 | $-49.0M | $2.3B | ||
| Q1 25 | $-60.8M | $1.4B | ||
| Q4 24 | $-55.0M | $4.8B | ||
| Q3 24 | $-50.7M | $3.6B | ||
| Q2 24 | $-62.8M | $2.5B | ||
| Q1 24 | $-61.3M | $689.0M |
自由现金流ALECAMGN
| Q4 25 | — | $961.0M | ||
| Q3 25 | $-32.5M | $4.2B | ||
| Q2 25 | $-49.1M | $1.9B | ||
| Q1 25 | $-60.8M | $980.0M | ||
| Q4 24 | $-55.2M | $4.4B | ||
| Q3 24 | $-50.9M | $3.3B | ||
| Q2 24 | $-63.1M | $2.2B | ||
| Q1 24 | $-61.9M | $459.0M |
自由现金流率ALECAMGN
| Q4 25 | — | 9.7% | ||
| Q3 25 | -997.6% | 44.4% | ||
| Q2 25 | -623.0% | 20.8% | ||
| Q1 25 | -1655.0% | 12.0% | ||
| Q4 24 | -101.8% | 48.4% | ||
| Q3 24 | -332.1% | 39.0% | ||
| Q2 24 | -418.6% | 26.5% | ||
| Q1 24 | -389.3% | 6.2% |
资本支出强度ALECAMGN
| Q4 25 | 0.0% | 6.5% | ||
| Q3 25 | 0.3% | 4.6% | ||
| Q2 25 | 0.1% | 4.0% | ||
| Q1 25 | 0.5% | 5.0% | ||
| Q4 24 | 0.3% | 4.1% | ||
| Q3 24 | 1.4% | 3.0% | ||
| Q2 24 | 2.2% | 2.8% | ||
| Q1 24 | 3.4% | 3.1% |
现金转化率ALECAMGN
| Q4 25 | — | 1.20× | ||
| Q3 25 | — | 1.46× | ||
| Q2 25 | — | 1.59× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 7.61× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 3.30× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALEC
暂无分部数据
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
